Advertisement

Ischemic Stroke

  • Steven K. Feske
    Correspondence
    Requests for reprints should be addressed to Steven K. Feske, MD, Neurology Department, Boston Medical Center, 72 East Concord Street, Collamore C3, Boston, MA, 02118.
    Affiliations
    Department of Neurology, Boston Medical Center, Boston University School of Medicine, Boston, Mass
    Search for articles by this author

      Abstract

      This concise review of the epidemiology, pathophysiology, evaluation, acute management, and prevention of ischemic stroke targets internists, family practitioners, and emergency physicians who manage patient with stroke.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Virani SS
        • Alonso A
        • Benjamin EJ
        • et al.
        Heart disease and stroke statistics –2020 update: a report of the American Heart Association.
        Circulation. 2020; 141: e139-e596
        • The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group
        Tissue plasminogen activator for acute ischemic stroke.
        N Engl J Med. 1995; 333: 1581-1588
        • Hacke W
        • Kaste M
        • Bluhmki E
        • et al.
        Thrombolyssis with alteplase 3 to 4.5 hours after acute ischemic stroke.
        N Engl J Med. 2008; 359: 1317-1329
        • Berkkemer OA
        • Fransen PSS
        • Beumer D
        • et al.
        for the MR CLEAN Investigators. A randomized trial of intraarterial treatment for acute ischemic stroke.
        N Engl J Med. 2015; 372: 11-20
        • Goyal M
        • Demchuk AM
        • Menon BK
        • et al.
        Randomized assessment of rapid endovascular treatment of ischemic stroke.
        N Eng J Med. 2015; 372: 1019-1030
        • Campbell BCV
        • Mitchell PJ
        • Kleinig TJ
        • et al.
        for the EXTEND-IA Investigator. Endovascular therapy for ischemic stroke with perfusion-imaging selection.
        N Engl J Med. 2015; 372: 1009-1018
        • Saver JL
        • Goyal M
        • Bonafe A
        • et al.
        Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke.
        N Engl J Med. 2015; 372: 2285-2295
        • Jovin TG
        • Chamorro A
        • Cobo E
        • et al.
        Thrombectomy within 8 hours after symptom onset in ischemic stroke.
        N Engl J Med. 2015; 372: 2296-2306
        • Nogueira RG
        • Jadhav AP
        • Haussen DC
        • et al.
        Thrombectomy 6 to 24 hours after stroke with a mismatch between deficit and infarct.
        N Engl J Med. 2018; 378: 11-21
        • Albers GW
        • Marks MP
        • Kemp S
        • et al.
        Thrombectomy for stroke at 6 to 16 hours with selection by perfusion imaging.
        N Engl J Med. 2018; 378: 708-718
        • Antithrombotic Trialist’ (ATT) Collaboration
        Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomized trials.
        Lancet. 2009; 373: 1849-1860
        • CAPRIE Steering Committee
        A randomized, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
        Lancet. 1996; 348: 1329-1339
        • Diener HC
        • Cunha ZL
        • Forbes C
        • et al.
        European Stroke Prevention Study 2. Dipyridamole and acetylsalicyclic acid in the secondary prevention of stroke.
        J Neurol Sci. 1996; 143: 1-13
        • Diener H-C
        • Bogousslavsky J
        • Brass LM
        • et al.
        Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomized, double-blind, placebo-controlled trial.
        Lancet. 2004; 364: 331-337
        • Bhatt DL
        • Fox KAA
        • Hacke W
        • et al.
        Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events.
        N Engl J Med. 2006; 354: 1706-1717
        • Sacco RL
        • Diener H-C
        • Yusuf S
        • et al.
        Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
        N Engl J Med. 2008; 359: 1238-1251
        • Johnston SC
        • Gress DR
        • Erowner WS
        • et al.
        Short-term prognosis after emergency-department diagnosis of transient ischemic attack.
        JAMA. 2000; 284: 2901-2906
        • Wang Y
        • Wang Y
        • Zhao X
        • et al.
        Clopidogrel with aspirin in acute minor stroke or transient ischemic attack.
        N Engl J Med. 2013; 369: 11-19
        • Johnston SC
        • Easton JD
        • Farrant M
        • et al.
        Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA.
        N Engl J Med. 2018; 379: 215-225
        • Lip GY
        • Nieuwlaat R
        • Pisters R
        • et al.
        Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation.
        Chest. 2010; 137: 263-272
        • Singer DE
        • Chang Y
        • Fang MC
        • et al.
        The net clinical benefit of warfarin anticoagulation in atrial fibrillation.
        Ann Intern Med. 2009; 151: 297-305
        • Granger CB
        • Alexander JH
        • McMurray JJV
        • et al.
        Apixaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2011; 365: 981-992
        • Patel MR
        • Mahaffey KW
        • Garg J
        • et al.
        Rivaroxaban versus warfarin in nonvalvular atrial fibrillation.
        N Engl J Med. 2011; 365: 883-891
        • Giugliano RP
        • Ruff CT
        • Braunwall E
        • et al.
        Edoxaban versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2013; 369: 2093-2104
        • Connolly SJ
        • Ezekowitz MD
        • Yusuf S
        • et al.
        Dabigatran versus warfarin in patients with atrial fibrillation.
        N Engl J Med. 2009; 361: 1139-1151
        • Li A
        • Garcia DA
        • Lyman GH
        • Carrier M.
        Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis.
        Thrombosis Res. 2019; 173: 158-163
        • Eikelboom JW
        • Connolly SJ
        • Bosch J
        • et al.
        Rivaroxaban with or without aspirin in stable cardiovascular disease.
        N Engl J Med. 2017; 377: 1319-1330
        • The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
        High-dose atorvastatin after stroke or transient ischemic attack.
        N Engl J Med. 2006; 355: 349-359
        • Amarenco P
        • Kim JS
        • Labreuche J
        • et al.
        A comparison of two LDL cholesterol targets after ischemic stroke.
        N Engl J Med. 2020; 382: 9-19
        • North American Symptomatic Carotid Endarterectomy Trial Collaborators
        Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis.
        N Engl J Med. 1991; 325: 445-453
        • Barnett HJM
        • Taylor W
        • Eliasziw M
        • et al.
        Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis.
        N Engl J Med. 1998; 339: 1415-1425
        • Brott TG
        • Hobson RW
        • Howard G
        • et al.
        Stenting versus endarterectomy for treatment of carotid-artery stenosis.
        N Engl J Med. 2010; 363: 11-23
        • Walker MD
        • Marler JR
        • Goldstein M
        • et al.
        Endarterectomy for asymptomatic carotid stenosis.
        JAMA. 1995; 273: 1421-1428
        • MRC Asymptomatic Carotid Surgery Trial (ACST) Collaborative Group
        Prevention of disabling and fatal stroke by successful carotid endarterectomy in patients without recent neurological symptoms: randomized controlled trial.
        Lancet. 2004; 363: 1491-1502
        • Keyhani S
        • Cheng EM
        • Hoggatt KJ
        • et al.
        Comparative effectiveness of carotid endarterectomy vs initial medical therapy in patients with asymptomatic carotid stenosis.
        JAMA Neurol. 2020; 77: 1110-1121https://doi.org/10.1001/jamaneurol.2020.1427
        • Howard VJ
        • Meschia JF
        • Lal BK
        • et al.
        Carotid revascularization and medical management for asymptomatic carotid stenosis: protocol of the CREST-2 clinical trials.
        Int J Stroke. 2017; 12: 770-778
        • Kent DM
        • Ruthazer R
        • Weimar C
        • et al.
        An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.
        Neurology. 2013; 81: 619-625
        • Furlan AJ
        • Reisman M
        • Massaro J
        • et al.
        Closure or medical therapy for cryptogenic stroke with patent foramen ovale.
        N Engl J Med. 2012; 366: 991-999
        • Meier B
        • Kalesan B
        • Mattle HP
        • et al.
        Percutaneous closure of patent foramen ovale in cryptogenic embolism.
        N Engl J Med. 2013; 368: 1083-1091
        • Carroll JD
        • Saver JL
        • Thaler DE
        • et al.
        Closure of patent foramen ovale versus medical therapy after cryptogenic stroke.
        N Engl J Med. 2013; 368: 1092-1100
        • Saver JL
        • Carroll JD
        • Thaler DE
        • et al.
        Long-term outcomes of patent foramen ovale closure or medical therapy after stroke.
        N Engl J Med. 2017; 377: 1022-1032
        • Mas J-L
        • Derumeaux G
        • Guillon B
        • et al.
        Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke.
        N Engl J Med. 2017; 377: 1011-1021
        • Søndergaard L
        • Kasner SE
        • Rhodes JF
        • et al.
        Patent foramen ovale closure or antiplatelet therapy for cryptogenic stroke.
        N Engl J Med. 2017; 377: 1033-1042
        • The EC/IC Bypass Study Group
        Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke: Results of an international randomized trial.
        N Engl J Med. 1985; 313: 1191-1200
        • Powers WJ
        • Clarke WR
        • Grubb RL
        • et al.
        Extracranial-intracranial bypass surgery for stroke prevention in hemodynamic cerebral ischemia: the Carotid Occlusion Surgery Study randomized trial.
        JAMA. 2011; 306: 1983-1992
        • Hallemeier CL
        • Rich KM
        • Grubb RL
        • et al.
        Clinical features and outcome in North American adults with moyamoya phenomenon.
        Stroke. 2006; 37: 1490-1496
        • Chimowitz MI
        • Lynn MJ
        • Derdeyn CP
        • et al.
        Stenting versus aggressive medical therapy for intracranial arterial stenosis.
        N Engl J Med. 2011; 365: 993-1003
        • Zaidat OO
        • Fitzsimmons B-F
        • Woodward BK
        • et al.
        Stroke in patients with symptomatic intracranial stenosis: the VISSIT randomized clinical trial.
        JAMA. 2015; 313: 1240-1248
        • Alexander MJ
        • Zauner A
        • Chaloupka JC
        • et al.
        WEAVE trial: final results in 152 on-label patients.
        Stroke. 2019; 50: 889-894